EUVIMEDOpdag EUVIMED
Beobachtungsstudie

Coronavirus Disease-19-associated Mucormycosis: A Single-center Observational Study of 69 Patients

Dhirendra Shivprasad Yadav, Swati Arvind Chavan, Niteen Dattatray Karnik, Chaya Ashok Kumar, Rupal Nilesh Padhiyar, Desma D'Souza

Journal of The Association of Physicians of India · 2024

DOI: 10.59556/japi.72.0684 ↗

At a glance

Beobachtungsstudie in Journal of The Association of Physicians of India, 2024. Written by Dhirendra Shivprasad Yadav and 5 co-authors. Institution: Assistant Professor, Department of Medicine, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Mumbai, Maharash…. Major MEDLINE topics: Mucormycosis, COVID-19. Cited 1 times so far (Crossref); 29 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

BACKGROUND AND OBJECTIVES: We studied the clinical presentation, risk factors, complications, and in-hospital outcomes of patients with coronavirus disease 2019 (COVID-19)-associated mucormycosis (CAM). MATERIALS AND METHODS: A retrospective study was done on 69 COVID-19 patients with microbiologically proven mucormycosis admitted over a period of seven months from March 2021 to September 2021. RESULTS: All 69 mucormycosis patients (46 males, 23 females) had reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed COVID-19 infection. Their mean age was 52.8 years, with mucormycosis developing in 51 patients (73.9%) within 30 days of COVID-19 infection; 7 (10.1%) were positive on admission. Rhino-orbital-cerebral mucormycosis (ROCM) was the most common (40.3%), followed by rhino-orbital (37.3%) and sinonasal (22.4%). Diabetes mellitus was present in 98.6% of patients. Common symptoms of mucormycosis were facial pain, headache, facial swelling, and vision loss. During COVID-19, 88.4 and 52.5% received immunosuppressive treatment and zinc sulfate, respectively; 34.7% needed intensive care unit (ICU) admission. The mortality rate was 26.1%. On multivariate logistic regression analysis, the presence of chronic kidney disease, leukocytosis, ophthalmoplegia, oral/palate ulceration, current need for invasive ventilation, and past duration of oxygen therapy and zinc supplementation were significantly associated with mortality. Patients with current COVID-19 infection had severe disease with increased need for intensive care (57.1 vs 14.5%) and higher mortality (57.1 vs 22.6%) compared to mucormycosis patients with previous COVID-19 infection. INTERPRETATION AND CONCLUSION: Rhino-orbital-cerebral, rhino-orbital, and sinonasal were the most common presentations in cases of mucormycosis, with a mortality rate of 26.1%. COVID-19 coinfection predisposes patients with mucormycosis to severe disease with higher mortality.

Subjects

MeSH terms (MEDLINE)

MucormycosisCOVID-19HumansMaleMiddle AgedFemaleRetrospective StudiesAdultRisk FactorsAgedSARS-CoV-2IndiaAntifungal Agents

Substances

Antifungal Agents

Authors and institutions

  • Assistant Professor, Department of Medicine, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Mumbai, Maharashtra, India.
  • Professor, Department of Medicine, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Mumbai, Maharashtra, India.
  • Professor and Head of Department, Department of Medicine, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Mumbai, Maharashtra, India.
  • Additional Professor, Department of Microbiology, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Mumbai, Maharashtra, India, Corresponding Author.
  • Associate Professor, Department of Medicine, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Mumbai, Maharashtra, India.
  • Associate Professor, Department of Microbiology, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Mumbai, Maharashtra, India.

Cite

APA

Yadav, D. S., Chavan, S. A., Karnik, N. D., Kumar, C. A., Padhiyar, R. N., & D'Souza, D. (2024). Coronavirus Disease-19-associated Mucormycosis: A Single-center Observational Study of 69 Patients. Journal of The Association of Physicians of India. https://doi.org/10.59556/japi.72.0684

Vancouver

Yadav DS, Chavan SA, Karnik ND, Kumar CA, Padhiyar RN, D'Souza D. Coronavirus Disease-19-associated Mucormycosis: A Single-center Observational Study of 69 Patients. Journal of The Association of Physicians of India. 2024. doi:10.59556/japi.72.0684

BibTeX
@article{Yadav2024,
  author = {Yadav, Dhirendra Shivprasad and Chavan, Swati Arvind and Karnik, Niteen Dattatray and Kumar, Chaya Ashok and Padhiyar, Rupal Nilesh and D'Souza, Desma},
  title = {Coronavirus Disease-19-associated Mucormycosis: A Single-center Observational Study of 69 Patients},
  journal = {Journal of The Association of Physicians of India},
  year = {2024},
  doi = {10.59556/japi.72.0684}
}
Start for free →